Ferrer M, Garcia-Esteban R, Iniguez C, Costa O, Fernandez-Somoano A, Rodríguez-Delhi C, Ibarluzea J, Lertxundi A, Tonne C, Sunyer J, Julvez J. Head circumference and child ADHD symptoms and cognitive functioning: results from a large population-based cohort study. Eur Child Adolesc Psychiatry. 2019 Mar;28(3):377-88. doi: 10.1007/s00787-018-1202-4
Mauskopf J, Chirila C, Birt J, Boye KS, Bowman L. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget? Health Policy (New York). 2013 Apr 1;110(1):49-59.
Ramos R, Freire C, Julvez J, Fernandez MF, Garcia-Esteban R, Torrent M, Sunyer J, Olea N. Association of ADHD symptoms and social competence with cognitive status in preschoolers. Eur Child Adolesc Psychiatry. 2013 Mar;22(3):153-64. doi: 10.1007/s00787-012-0334-1
Dickey H, Ikenwilo D, Norwood P, Watson V, Zangelidis A. Utilisation of eye-care services: the effect of Scotland's free eye examination policy. Health Policy (New York). 2012 Dec;108(2-3):286-93. doi: 10.1016/j.healthpol.2012.09.006
Watson V, Sussex J, Ryan M, Tetteh E. Managing poorly performing clinicians: health care providers' willingness to pay for independent help. Health Policy (New York). 2012 Mar;104(3):260-71. doi: 10.1016/j.healthpol.2011.12.006
Richter A, Hicks KA, Earnshaw SR, Honeycutt AA. Allocating HIV prevention resources: a tool for state and local decision making. Health Policy (New York). 2008 Sep 1;87(3):342-9.
Wong WM, Hawe E, Li LK, Miller GJ, Nicaud V, Pennacchio LA, Humphries SE, Talmud PJ. Apolipoprotein AIV gene variant S347 is associated with increased risk of coronary heart disease and lower plasma apolipoprotein AIV levels. Circ Res. 2003;92(9):969-75.
Lovas K, Kalo Z, McKenna SP, Whalley D, Pentek M, Genti G. Establishing a standard for patient-completed instrument adaptations in Eastern Europe: experience with the Nottingham Health Profile in Hungary. Health Policy (New York). 2003 Jan 1;63(1):20.
McKenna SP, Whalley D. Assessment of biotechnology drugs: what are the issues? Letter to the editor. Health Policy (New York). 1999 Nov;49(3):195-7. doi: 10.1016/S0168-8510(99)00055-X